金融界8月23日消息,欧林生物披露投资者关系活动记录表显示,2024年上半年,公司核心产品吸附破伤风疫苗销售额整体稳健增长,同比增长6.8%左右。公司积极推进重组金葡菌疫苗Ⅲ期临床试验进度,截至2024年8月中旬,公司重组金葡菌疫苗Ⅲ期临床试验已入组4,100例左右。按照目前的入组速度,预计明年上半年能够完成全部入组。
English
Back
- Markets
- Features
- News
- Community
- Learn
- Help Center
- About
- Offers & Rewards
- Welcome RewardsOpen an account and get up to HKD1600!
- Enjoy limited-time 5%+5% returns on Cash PlusInvest any amount and enjoy a 5% average return on Cash Plus + 5% welcome reward
- Referral PromotionBring a friend and collect up to HK$600 in rewards
- Learn PremiumAnalyst 1V1 online teaching
- Stock TransferSwitch to Futu and get up to HK$7,000 in rewards
- English
- 繁體中文
- 简体中文
- Dark
- Light
欧林生物:2024年上半年吸附破伤风疫苗销售稳健增长,第三期金葡菌疫苗临床试验已入组4100例
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.